Processa Pharmaceuticals, Inc. (PCSA) stock
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.73+0.01 (+0.58%)
Close on Nov 17, 2026Market cap $4.83MP/E –Yield –
Processa Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Processa Pharmaceuticals's operating cash flow for the twelve months ending Dec 31, 2025 was -$11.39M. For fiscal 2025 it was -$11.39M. The highest annual figure on record is -$871.91K in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.39M | – |
| FY2024 | Dec 31, 2024 | -$11.25M | – |
| FY2023 | Dec 31, 2023 | -$8.06M | – |
| FY2022 | Dec 31, 2022 | -$9.61M | – |
| FY2021 | Dec 31, 2021 | -$8.72M | – |
| FY2020 | Dec 31, 2020 | -$3.14M | – |
| FY2019 | Dec 31, 2019 | -$2.75M | – |
| FY2018 | Dec 31, 2018 | -$3.71M | – |
| FY2017 | Dec 31, 2017 | -$1.65M | – |
| FY2016 | Dec 31, 2016 | -$2.16M | – |
| FY2015 | Dec 31, 2015 | -$871.91K | – |
| FY2014 | Dec 31, 2014 | -$2.69M | – |
| FY2013 | Dec 31, 2013 | -$2.54M | – |
| FY2012 | Dec 31, 2012 | -$1.89M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.73M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.55M | -5419.7% |
| Q2 FY2021 | Jun 30, 2021 | -$2.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.28M | – |
| Q3 FY2020 | Sep 30, 2020 | $29.19K | – |
| Q2 FY2020 | Jun 30, 2020 | -$350.58K | – |
| Q1 FY2020 | Mar 31, 2020 | -$546.45K | – |
| Q4 FY2019 | Dec 31, 2019 | -$613.49K | – |
| Q3 FY2019 | Sep 30, 2019 | -$721.76K | – |
| Q2 FY2019 | Jun 30, 2019 | -$807.47K | – |
| Q1 FY2019 | Mar 31, 2019 | -$607.43K | – |
| Q4 FY2018 | Dec 31, 2018 | -$463.98K | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.16M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.07M | -6487.5% |
| Q4 FY2017 | Dec 31, 2017 | -$675.79K | – |
| Q1 FY2017 | Mar 31, 2017 | -$58.70K | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.12M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.74K | – |
| Q2 FY2016 | Jun 30, 2016 | -$2.57K | – |
| Q1 FY2016 | Mar 31, 2016 | -$50.37K | – |
See a number that looks wrong?